A Pilot Study of the Effect of Minocycline on Cerebrospinal Fluid HIV-1 Infection
|ClinicalTrials.gov Identifier: NCT01064752|
Recruitment Status : Completed
First Posted : February 8, 2010
Last Update Posted : February 8, 2010
|Condition or disease||Intervention/treatment|
|HIV Infection||Drug: Minocycline|
This study is founded on a sequence of related hypotheses: 1. inflammatory responses related to activation of macrophages importantly contribute to the magnitude of CNS HIV infection by increasing the local production of viral progeny; 2. the tetracycline, minocycline, has anti-inflammatory properties which likely underlie studies showing that this drug can inhibit HIV-1 infection in macrophages and microglia in vitro and reduce simian immunodeficiency virus (SIV) encephalitis in macaques; 3. by reducing CNS monocyte/macrophage/microglial activation, minocycline will therefore reduce CNS HIV infection; 4. CSF will reflect or parallel (and thus serve as a 'model' of) brain infection and inflammation in this setting; 5. therefore, longitudinal CSF monitoring can assess the effect of minocycline on both CNS HIV infection and inflammation; 6. because the brain injury underlying AIDS dementia complex (ADC) and its pathological substrate, HIV encephalitis, critically involve inflammatory processes and, in the broad sense, immunopathology, minocycline might eventually prove useful as an adjunct to antiviral therapy in accelerating recovery from this condition (though importantly, this pilot study will not include ADC patients).
This will be an uncontrolled, open-labelled pilot study exploring whether minocycline has a measurable and selective effect on CSF HIV RNA concentration. There are no previous studies examining this effect in humans. We define a priori a 'biologically meaningful' effect to be an increase in the Δplasma-CSF HIV concentration of >0.5 log10 copies/mL of HIV RNA (i.e. an increase in the difference between plasma and CSF of >0.5 log10 copies/mL of HIV RNA compared to the baseline difference) in the face of unchanged or reduced plasma HIV RNA. Reductions in the absolute levels of CSF and plasma HIV as well as reductions in CSF inflammatory markers and T cell activation will also be of interest.
This study will serve as an initial exploration of the possible therapeutic effect of minocycline on CNS HIV infection. Our overall strategy is to begin with this pilot study, and if the results look promising (biological effect and lack of toxicity), to use these results to design a controlled trial, either as a single or multi-institutional study.
Additionally, this study shares an almost identical design with another proposed study examining the effects of atorvastatin on CSF HIV infection. While neither of these studies is controlled, they will yield pilot comparative results.
|Study Type :||Observational|
|Actual Enrollment :||7 participants|
|Official Title:||A Pilot Study of the Effect of Minocycline on Cerebrospinal Fluid HIV-1 Infection|
|Study Start Date :||April 2005|
|Actual Primary Completion Date :||October 2009|
|Actual Study Completion Date :||October 2009|
HIV-1 infected, not on anti-retroviral medication
100 mg po bid for 8 weeks
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01064752
|Principal Investigator:||Richard W Price, MD||University of California, San Francisco|